Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil - Trial NCT04039698
Access comprehensive clinical trial information for NCT04039698 through Pure Global AI's free database. This phase not specified trial is sponsored by Hospital de Clinicas de Porto Alegre and is currently Not yet recruiting. The study focuses on Chronic Hepatitis C. Target enrollment is 144 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hospital de Clinicas de Porto Alegre
Timeline & Enrollment
N/A
Aug 23, 2019
Nov 01, 2021
Primary Outcome
Sustained virologic response
Summary
The study is a non-randomized, single group clinical trial on monitoring hepatitis C therapy
 using telemedicine. Patients with chronic hepatitis C without cirrhosis will be treated with
 the pangenotypic regimen of direct acting antivirals sofosbuvir and velpatasvir for 12 weeks
 after a single visit to the clinic, in which treatment will be prescribed. Patients will be
 then monitored by telemedicine tools, like instant message application, telephone and video
 calls and by his or her primary physician when needed. Twelve weeks after treatment
 conclusion, hepatitis C virus RNA levels will be measured on a blood sample, indicating the
 cure rate and efficacy of this protocol on HCV treatment.
 
 The primary objective of the study is to address the feasibility and applicability of the
 usage of telemedicine tools to increase access and monitor HCV treatment with direct-acting
 antivirals in public health in Brazil.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04039698
Non-Device Trial